Professor Dr. Per Borghammer explains the brain-first vs. body-first model of Parkinson’s disease, which consists of two distinct pathways of disease progression starting from the gut or nose.
Learn how these findings could potentially pave the way for personalized medicine and new treatments to stop Parkinson’s disease in its tracks.
Related content
Overview of three therapeutic strategies targeting alpha-synuclein in the development of disease-modifying treatments for Parkinson’s disease
Graphical representation of how various treatment strategies can impact disease progression in Parkinson’s disease, from symptom relief to potential cure
Illustration of how COMT inhibitors increase dopamine availability in Parkinson’s disease by preventing the breakdown of L-DOPA